Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Steven P. Treon(Dana-Farber Cancer Institute), Ranjana H. Advani(Stanford Medicine), James L. Zehnder(Cancer Prevention Institute of California), Zeena Salman(Revolution Medicines (United States)), Fong Clow(Pharmacyclics (United States)), Nancy L. Harris(World Resources Institute), Sandra Kanan(University of Washington Medical Center), Irene M. Ghobrial(Dana-Farber Cancer Institute), Jorge J. Castillo(Dana-Farber Cancer Institute), Zachary R. Hunter(Harvard University), Jon C. Aster(Brigham and Women's Hospital), Christopher J. Patterson(Dana-Farber Cancer Institute), Gaurav Varma(NYU Langone Health), Jacob P. Laubach(Harvard University), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Thorsten Graef(Beth Israel Deaconess Medical Center), Scott J. Rodig(Brigham and Women's Hospital), Kirsten Meid(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Kimon V. Argyropoulos(Memorial Sloan Kettering Cancer Center), Jianling Li(Pharmacyclics (United States)), Rebecca Green(Memorial Sloan Kettering Cancer Center), Mei Cheng(Pharmacyclics (United States)), Diane Warren(Dana-Farber Cancer Institute), Christina Tripsas(Dana-Farber Cancer Institute), Lian Xu(Huazhong Agricultural University), Yang Cao(Nanjing Tech University)
Cited by 937
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k